{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T11:18:45Z","timestamp":1775042325339,"version":"3.50.1"},"reference-count":10,"publisher":"SLACK, Inc.","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Psychosoc Nurs Ment Health Serv"],"published-print":{"date-parts":[[2010,7]]},"abstract":"<jats:p>Understanding the particular pharmacology of different antidepressant drugs can help explain their adverse effects when they are discontinued. For all antidepressant drugs, abruptly stopping them can sometimes result in \u201crebound\u201d hypomania or mania. Antidepressant drugs having anticholinergic effects often are associated with a discontinuation syndrome characterized by cholinergic rebound, with symptoms of nausea, vomiting, abdominal cramping, sweating, headache, and muscle spasms. Discontinuation of monoamine oxidase inhibitor drugs sometimes results in flu-like symptoms, dysphoria, restlessness, tachycardia, hypertension, and a delirium-like state. Serotonergic antidepressant drugs are sometimes associated with a distinct discontinuation syndrome characterized by dizziness, weakness, nausea, headache, lethargy, insomnia, anxiety, poor concentration, and paresthesias. Adverse discontinuation effects can occur with all types of antidepressant drugs, but only rarely would they be considered serious. To minimize adverse discontinuation effects and to reduce the risk of relapse or recurrence of the underlying treated condition, tapering antidepressant medication is prudent for all patients.<\/jats:p>","DOI":"10.3928\/02793695-20100527-98","type":"journal-article","created":{"date-parts":[[2010,7,7]],"date-time":"2010-07-07T20:33:21Z","timestamp":1278534801000},"page":"9-12","source":"Crossref","is-referenced-by-count":23,"title":["Potential Adverse Effects of Discontinuing Psychotropic Drugs"],"prefix":"10.3928","volume":"48","member":"2308","reference":[{"key":"e_1_3_1_2_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v65n0716"},{"key":"e_1_3_1_3_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2010.09060880"},{"key":"e_1_3_1_4_1","volume-title":"Goodman & Gilman\u2019s the pharmacological basis of therapeutics","author":"Brunton L.L.","year":"2006","unstructured":"Brunton L.L., Lazo J.S., Parker K.L., Buxton I.L.O., Blumenthal D. (Eds.). (2006). Goodman & Gilman\u2019s the pharmacological basis of therapeutics (11th ed.). New York: McGraw-Hill.","edition":"11"},{"key":"e_1_3_1_5_1","doi-asserted-by":"publisher","DOI":"10.1177\/026988119801200311"},{"key":"e_1_3_1_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0306-9877(98)90112-8"},{"key":"e_1_3_1_7_1","unstructured":"Muzina D.J. (2010). Discontinuing an antidepressant? Tapering tips to ease distressing symptoms. Current Psychiatry 9 (3). Retrieved from http:\/\/www.currentpsychiatry.com\/article_pages.asp?AID=8415&UID="},{"key":"e_1_3_1_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-200206001-00004"},{"key":"e_1_3_1_9_1","volume-title":"Kaplan & Sadock\u2019s pocket handbook of psychiatric drug treatment","author":"Sadock B.J.","year":"2006","unstructured":"Sadock B.J., Sadock V.A., Sussman N. (2006). Kaplan & Sadock\u2019s pocket handbook of psychiatric drug treatment (4th ed.). Philadelphia: Lippincott Williams & Wilkins.","edition":"4"},{"key":"e_1_3_1_10_1","volume-title":"Manual of clinical psychopharmacology","author":"Schatzberg A.F.","year":"2007","unstructured":"Schatzberg A.F., Cole J.O., DeBattista C. (2007). Manual of clinical psychopharmacology (6th ed.). Arlington, VA: American Psychiatric Publishing.","edition":"6"},{"issue":"1","key":"e_1_3_1_11_1","first-page":"S25","article-title":"Sibutramine: A review of the pharmacology of a novel anti-obesity agent","volume":"21","author":"Stock M.J.","year":"1997","unstructured":"Stock M.J. (1997). Sibutramine: A review of the pharmacology of a novel anti-obesity agent. International Journal of Obesity and Related Metabolic Disorders, 21(Suppl. 1), S25\u2013S29.","journal-title":"International Journal of Obesity and Related Metabolic Disorders"}],"container-title":["Journal of Psychosocial Nursing and Mental Health Services"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.slackinc.com\/doi\/resolver.asp?doi=10.3928\/02793695-20100527-98","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T12:49:04Z","timestamp":1683118144000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.healio.com\/doi\/10.3928\/02793695-20100527-98"}},"subtitle":["Part 2: Antidepressant Drugs"],"editor":[{"given":"Robert H.","family":"Howland","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2010,7]]},"references-count":10,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2010,7]]}},"alternative-id":["10.3928\/02793695-20100527-98"],"URL":"https:\/\/doi.org\/10.3928\/02793695-20100527-98","relation":{},"ISSN":["0279-3695","1938-2413"],"issn-type":[{"value":"0279-3695","type":"print"},{"value":"1938-2413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,7]]}}}